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To complement the existing treatment guidelines for all tumour types, ESMO organizes consensus conferences to
focus on specific issues in each type of tumour. In this setting, a consensus conference on the management of
lymphoma was held on 18 June 2011 in Lugano, next to the 11th International Conference on Malignant Lymphoma.
The conference convened ∼30 experts from all around Europe, and selected six lymphoma entities to be addressed;
for each of them, three to five open questions were to be addressed by the experts. For each question, a
recommendation should be given by the panel, referring to the strength of the recommendation based on the level of
evidence. This consensus report focuses on the three less common lymphoproliferative malignancies: marginal zone
lymphoma, mantle cell lymphoma, and peripheral T-cell lymphomas. A first report had focused on diffuse large B-cell
lymphoma, follicular lymphoma, and chronic lymphocytic leukaemia.
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Methodology
The conference convened ∼30 experts from all around Europe, and
selected six lymphoma entities to be addressed; for each of them, three
to five open questions were to be addressed by the experts. For each
question, a recommendation should be given by the panel, referring to
the strength of the recommendation based on the level of evidence. This
consensus report focuses on the three less common lymphoproliferative
malignancies: marginal zone lymphoma (MZL), mantle cell lymphoma
(MCL), and peripheral T-cell lymphomas (TCLs). A first report had
focussed on diffuse large B-cell lymphoma (DLBCL), follicular
lymphoma (FL), and chronic lymphocytic leukaemia (CLL). Level of
evidence and grade of recommendation have been adapted from the
Infectious Diseases Society of American-United States Public Health
Service Grading System (Table 1).
1. Marginal zone lymphoma
In the last WHO classification, the MZL including the extra-
nodal MZL of MALT type (MALT lymphoma), the splenic
MZL (SMZL) (with or without villous lymphocytes), and nodal
MZL NMZL (with or without monocytoid B cells) are three
distinct clinical entities with specific diagnostic criteria and
different behaviour and therapeutic implications [1]. A
committee of experts including haematologists/oncologists and
haematopathologists has defined three crucial issues to manage
patients with MZLs: to make the correct diagnosis and evaluate
the biological prognosis of the disease; to distinguish between
localized disease, essentially MALT lymphomas, and
disseminated disease, SMZL and NMZL; and to propose the
best treatment.
1.1 Pathology and prognosis of MZL
The diagnosis should be in accordance with the current WHO
classification [1]. The diagnosis of MZL, as in other
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lymphomas should be confirmed by review by an expert
haematopathologist. Differentiation from other lymphomas
that can mimic MZLs should be confirmed (Table 2).
For extra-nodal MZL assessment of a potential associated
large B-cell lymphoma is essential by analysis of extra-follicular
components for transformed large B cells. Of particular note is
the fact that the presence of lymphoepithelial lesions is neither
essential for the diagnosis of extra-nodal MZL nor is their
presence absolutely specific for this entity as they can be seen
both in some reactive conditions and in other low-grade
lymphomas.
The diagnosis of SMZL at present does not strictly require a
splenectomy [2]. Characteristic features to allow this have been
established following the review of a large series of cases in
which the diagnosis has been confirmed by review of splenic
histology [3].
In some cases, the definitive diagnosis may not be possible.
Of note is the fact that cytoplasmic villi will not be seen in all
cases (and may be lost if the blood has been store for
prolonged period with anticoagulant) and not all
lymphoproliferations where the cells have villi equate to SMZL.
No consistent prognostic markers have been identified that
are sufficiently significant to alter initial clinical management
in MZL. Studies for t(11;18)(p21; p21) would be considered
Table 1. Level of evidence (Infectious Diseases Society of American-
United States Public Health Service Grading System)
I Evidence from at least one large randomized, controlled trial of
good methodological quality (low potential for bias) or meta-
analyses of well-conducted randomized trials without
heterogeneity
II Small randomized trials of large randomized trials with a suspicion
of bias (lower methodological quality) or meta-analyses of such
trials or of trials demonstrated heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case–control studies
V Studies without control group, case reports, experts opinions
Grade for recommendation
A Strong evidence for efficacy with a substantial clinical benefit,
strongly recommended
B Strong or moderate evidence for efficacy but with a limited clinical
benefit, generally recommended
C Insufficient evidence for efficacy or benefit does not outweigh the
risk or the disadvantages (adverse events, costs, etc.), optional
D Moderate evidence against efficacy or for adverse outcome,
generally not recommended
E Strong evidence against efficacy or for adverse outcome, never
recommended
Table 2. Recommended procedures for initial staging and follow-up of patients with disseminated marginal zone lymphoma
Procedures Recommendations Expected results
At diagnosis Follow-up
Full blood count M M Presence or absence of anaemia, thrombocytopenia, neutropenia, lymphocytosis
Reticulocytes–DAT R O
Blood cytology M O Small lymphoid cells having a round nucleus with condensed chromatin and
basophilic cytoplasm, with frequent short villi
Blood flow cytometry (FCM) M R Mandatory: CD5−, CD10−, CD19+, CD23−, CD27+, CD43−, FMC7±, kappa/
lambda
Optional: CD20+, CD79b+, CD43±, CD103−, bcl-2+, annexin A1−, moderate to
strong intensity of IgM and IgD or Ig M alone; in rare cases, IgG or IgA—
expression of CD5 in 15%–20%—expression of CD23 in 30% of case—Score
Matutes ≤3
Serology for HCV M O If HCV positive, RT-PCR for HCV-RNA and virus genotyping
Cryoglobulins M if HCV+ O
Serology for HBV and HIV M O
CT scan M M SMZL: massive splenomegaly—NMZL: disseminated disease
GD endoscopy + ENT evaluation R O Detection of occult localization at MALT sites
BM aspirate: cytology and FC M O Identical to blood
BM biopsy M O See morphology section
Splenectomy O O See morphology section
Lymph node biopsy O O See morphology section
Autoimmune screening O O ANA, anti-DNA, AMA, anti-thyroid, RF; If clinical symptoms circulating
anticoagulant (lupic or cardiolipidic), acquired vWD, acquired deficit in C1 ester.
FISH and cytogenetics O O SMZL: trisomy 3q (85%) del or translocation of 7q32 (40%) trisomy 18, 17q
isochromosome, 13q14 deletion, and structural abnormalities of chr 1; xclusion of t
(11;14)
NMZL: gains of chr 3 and 18q23—lack of 7q loss
IgVH status O O IgVH mutated in two-third of the cases—IgVH unmutated in one-third of the cases
Biased usage: SMZL: VH1.2, VH1–2, VH3–23, VH4–34 genes; NMZL VH4-34
M, mandatory; R, recommended; O, optional; IgM, immunoglobulin M; IgD, immunoglobulin D; Ig, immunoglobulin; IgA, immunoglobulin A;
IgG, immunoglobulin G; CT, computer tomography; ENT, ear nose and throat.
special article Annals of Oncology
 | Dreyling et al. Volume 24 | No. 4 | April 2013
 by guest on N
ovem
ber 21, 2016
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
optional in the assessment of gastric MALT lymphoma, as they
may give an indication of the likelihood of response of the
lymphoma to Helicobacter pylori eradication alone.
1.1 Consensus statement
In all cases, but particularly for NMZL, the histological
diagnosis must be established in knowledge of the full clinical
and radiological presentation.
Level of evidence: IV
Grade of recommendation: A
1.2 Consensus statement
A minimum panel of immunocytochemical stains should
include CD20, CD10, CD5, and cyclinD1.
Level of evidence: IV
Grade of recommendation: B
1.3 Consensus statement
The diagnosis of SMZL can be confidently achieved by the
combination of peripheral blood and bone marrow aspirate
morphology and flow cytometry (FC) and of the findings of
bone marrow trephine biopsy histology with
immunocytochemistry by expert haematopathologists and
haematologists/oncologists [3].
Level of evidence: IV
Grade of recommendation: B
1.2 Localized marginal zone lymphoma: Diagnostic
and therapeutic measures
Localized MZL is mainly represented by extra-nodal MZL of
MALT type, that can however be disseminated in 25% of the
cases [4–6]. We focused on two important issues for the
management of the patients with extra-nodal MZL of MALT
type: the staging and the treatment.
1.2.1 INITIAL STAGING PROCEDURES
The following procedures are considered mandatory in gastric
MALT lymphoma:
Gastroduodenal endoscopy with multiple biopsies taken
from each region of the stomach, duodenum, gastro-
oesophageal junction and from any abnormal-appearing site;
H. pylori status must be evaluated. If clinically indicated, head
and neck magnet resonance tomography (MRT) studies and
other imaging may be performed.
The following procedures are recommended in:
• Gastric MALT lymphoma: endoscopic ultrasound to evaluate
the regional lymph nodes and gastric wall infiltration.
Optional: fluorescence in situ hybridization (FISH) for the t
(11;18) translocation.
For specific sites such as:
• Small intestine (immunoproliferative small intestinal disease,
IPSID): Campylobacter Jejuni search in the tumour biopsy by
polymerase chain recation (PCR), immunohistochemistry or
in situ hybridization may be carried out.
• Large intestine: colonoscopy.
• Lung: Bronchoscopy + bronchoalveolar lavage.
• Salivary glands: Ear/nose/throat examination and ultrasound.
Association with Sjögren syndrome to eliminate (anti-SSA or
anti-SSB antibodies) should be investigated.
• Thyroid: echography ± computer tomography (CT) scan of
the neck and thyroid function tests.
• Ocular adnexa: MRT (or CT scan) and ophthalmologic
examination. Chlamydia psittaci in the tumour biopsy and
blood mononuclear cells by PCR may be considered.
• Breast: mammography and MRT (or CT scan).
• Skin: Borrelia Burgdorferi in the tumour biopsy by PCR (in
endemic areas) may be considered.
The value of positron emission tomography (PET) scan is
controversial and has uncertain clinical utility and is not
recommended.
1.4 Consensus statement
The following exams are mandatory: history and physical exam
[including lymph node regions, eye and ear, nose and throat
(ENT) areas, liver and spleen evaluation; complete blood
counts and basic biochemical studies], including evaluation of
renal and liver function, lactate dehydrogenase (LDH) and β2-
microglobulin, serum protein immunofixation, human
immundeficiency virus (HIV), hepatitis C virus (HCV), and
hepatitis B virus (HBV) serology; CT scan of the chest,
abdomen, and pelvis; bone marrow aspirate and biopsy
recommended.
Level of evidence: IV
Grade of recommendation: B
1.2.2 TREATMENT
Treatment has been discussed considering two specific
scenarios: gastric MALT lymphoma, H. pylori positive,
stage I–II, and the others MALT lymphoma (non-gastric
MALT lymphoma and gastric patients who failed to respond to
H. pylori eradication.
• Gastric MALT lymphoma, H. pylori positive, stage I–II
H. pylori eradication therapy must be given to all gastric
MALT lymphomas, independently of stage or histological
grade. The outcome of H pylori eradication therapy should be
checked by urea breath test (or by a monoclonal stool antigen
test) at least 6 weeks after eradication therapy and at least 2
weeks after PPI withdrawal.
• Non-gastric MALT lymphoma and gastric patients who failed
to respond to H. pylori eradication
Involved Field Radiotherapy may be a reasonable option
only for localized stage. Chemotherapy, or immunotherapy or
in combination are effective in patients with MALT lymphoma
of all stages. There is no definitive evidence in favour of one of
these two modalities in localized gastric MALT lymphoma, but
the preferred choice depends very much on the local expertise
of the attending physicians. An important issue is that patients
with t(11;18) will most probably be unresponsive to alkylating
agents as sole treatment.
As in other disseminated low-grade lymphomas, rituximab
plus chemotherapy would be the best choice when treatment is
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needed, but there is not yet a standard best chemotherapy to
be recommended.
If clinical trials are available, patients should be included.
Besides clinical trials, a therapeutic approach similar to other
indolent lymphomas is always a good decision. Eradication
therapy with antibiotics in MALT lymphoma arising outside
the stomach remains investigational.
1.5. Consensus statement
In gastric MALT lymphoma the first step of treatment should
be H Pylori eradication (PPI + clarithromycin-based triple
therapy with either amoxicillin or metronidazole for 10–14
days).
Level of evidence: III
Grade of recommendation: A
H. pylori-negative patients with gastric MALT lymphoma
may also receive anti-H pylori treatment
Level of evidence: IV
Grade of recommendation: C
1.2.3 FOLLOW-UP/MONITORING
While non-gastric sites can be re-evaluated as any other low-
grade lymphoma (clinical exam, laboratory work-up, imaging,
biopsy of residual lesions), sequential evaluation of gastric
biopsies remains an essential follow-up procedure for gastric
MZL to exclude the possibility of persistent significant disease,
even if mucosa is normal and to look for early epithelial
changes, which may be related to gastric carcinoma,
particularly in patients with persistent H. pylori infection.
Unfortunately, the interpretation of lymphoid infiltrate in
post-treatment gastric biopsies can be very difficult and there
are no uniform criteria for the definition of histological
remission. Comparison with previous biopsies should be
carried out to assess response, and we recommend the GELA
scoring system as a reproducible method for this [7]. The
clinical decision should always be the result of close interaction
between clinicians and pathologists. H. pylori eradication
should be documented at least 6 weeks after the antibiotic
treatment. Then, a strict endoscopic follow-up is
recommended, with multiple biopsies taken 2–3 months after
treatment, and subsequently, at least twice per year for 2 years,
to monitor the histological regression of the lymphoma.
Gastric MALT lymphomas have limited tendency to distant
spreading and to histological transformation. Transient
apparent histological local relapses are occasionally observed
but they have to be maintained in order to consider a relapse,
as the changes reflect the limitations of small tissue and in
addition tend to be self-limiting, especially in the absence of
H. pylori reinfection [8].
Nevertheless, a long-term careful endoscopic and systemic
(clinical exam, blood counts and minimal adequate
radiological or ultrasound examinations) follow-up every 12
(−18) months is recommended for all patients. Indeed, the risk
of gastric adenocarcinoma among patients diagnosed with
gastric MALT lymphoma has been reported to be six-fold
higher than in the general population. Of important note, if
only microscopic gastric lesion is seen during follow-up, no
treatment should be initiated.
1.6 Consensus statement
In case of persistent but stable residual disease or histological
relapse (without distant dissemination and/or gross endoscopic
tumour), a watch-and-wait policy appears to be safe [9].
Level of evidence: IV
Grade of recommendation: C
1.3 Disseminated MZL
Disseminated MZL include SMZL, which is associated with
blood and bone marrow infiltration in more than 95% of the
cases, and NMZL, presenting with more or less extended
systemic lymphadenopathy in the vast majority of the cases.
Important questions about the management of these
lymphomas are staging, prognostic factors and treatment.
1.3.1 STAGING
Mandatory initial staging includes full blood and differential
counts, biochemistry including renal and liver function tests,
protein electrophoresis, calcium, LDH and β2-microglobulin,
serum and urine immunofixation, FC, bone marrow aspirate
with morphology and FC, bone marrow trephine biopsy,
complete chest and abdominal CT scan (alternatively, in some
occasions NMR), serology for HCV (if positive, including PCR
for HCV-RNA in and virus genotyping), cryoglobulins and
cryocrit if HCV positivity, HBV markers and HIV serology
and H. pylori (in case of gastric symptoms).
There are no data supporting the clinical utility of
abdominal sonography and PET in the routine staging of
disseminated MZL [10]. Abdominal sonography could be
considered in complement of CT scan for the detection of
splenic focal lesions while PET scan investigation may be
considered in selected cases (i.e. if clinical and/or laboratory
data suggest a transformation to high-grade histology, or to
guide the decision which lymph node should be biopsied).
We also recommend to perform the following exams: blood
smear examination, reticulocyte count + direct antiglobulin test
(DAT), gastroduodenal endoscopy + ENT evaluation if
clinically indicated especially in NMZL to exclude extra-nodal
localizations.
We consider autoimmune screening, FISH, and cytogenetics
optional.
1.7 Consensus statement
Recommended procedures for initial staging of patients with
disseminated MZL are based on well-described clinico-
pathological case series of SMZL [10–15], NMZL [4, 16, 17,
18–22], and non-MALT MZL [17] (Table 1).
Level of evidence: III
Grade of recommendation: C
1.3.2 PROGNOSTIC FACTORS
The Integruppo Italiano Linfomi analysed 309 patients with
SMZL and proposed a prognostic score validated in a split
sample [10]. This score, using three variables (haemoglobin
level <12 g/dl, LDH level greater than normal and albumin
level <3.5 g/dl) allows the identification of a low-, intermediate,
and high-risk group of patients [10]. Progression may be
associated or not with histological transformation to DLBCL,
and is more frequent in presence of peripheral lymph node
involvement [23, 24].
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NMZL reports have been limited to small series of patients,
and specific prognostic factors are lacking.
1.8 Consensus statement
Regarding the prognostic assessment of SMZL, high
lymphocyte count, abnormal levels of β2-microglobulin and
LDH, or infiltration of non-haematopoietic sites have been
found to be associated with shorter overall survival (OS) and
progression-free survival (PFS) [11–15].
Level of evidence: IV
Grade of recommendation: C.
1.3.3 TREATMENT
For NMZL, no specific recommendation is available, but the
disease is usually disseminated and treatment should be
planned according to the therapeutic principles adopted for
FL.
For SMZL, therapeutic options are splenectomy [12, 25],
chemotherapy [10, 26, 27], rituximab alone [28–30], or
rituximab–chemotherapy [15, 27, 28]. Rituximab therapy
produces a quick response with a high overall (>80%) and
complete (>40%) response rate with negligible toxicity but
optimal schedule and long-term outcome have not been
defined yet. Rituximab at 375 mg/m2 × 4 weekly doses is a
reasonable first-line therapy and a real and less traumatic
alternative to splenectomy.
1.9 Consensus statement
Criteria for initiating treatment in SMZL are the following: [3]
progressive or painful splenomegaly; one of the following
symptomatic/progressive cytopenias: haemoglobin <10 g/dl,
platelets <80 000/µl; neutrophils <1000/µl. Of note, AHA
should be specifically treated.
Level of evidence V
Grade of recommendation: B
1.10 Consensus statement
Immunochemotherapy is indicated for fit patients with
disseminated disease, constitutional symptoms, and/or signs of
high-grade transformation.
Level of evidence: IV
Grade of recommendation: C
Regarding treatment of NMZL, in advanced stage
immunochemotherapy should be the treatment of choice.
Level of evidence: IV
Grade of recommendation: C
1.11 Consensus statement
In patients with NMZL or SMZL and concurrent HCV-related
chronic hepatitis who do not need immediately conventional
treatment of lymphoma, antiviral treatment with pegylated
interferon and ribavirin should be considered as first treatment
[31–33].
Level of evidence: IV
Grade of recommendation: C
1.3.4 RESPONSE CRITERIA
Considering the peculiar clinical presentation of SMZL, we
recommend to employ following specific criteria for response
assessment: [3]
Complete response
• Resolution of organomegaly (spleen longitudinal
diameter < 13 cm).
• Haemoglobin >12 g/dl, platelets >100 × 109/l, and
neutrophils >1.5 × 109/l.
• No evidence of circulating clonal B cells by FC (light chain-
restricted B cells).
• No evidence of BM infiltration detected by
immunohistochemistry.
• Optional: negative DAT and normal PET scan (if positive at
diagnosis).
Partial response
• Regression of ≥50% in all the measurable disease
manifestations.
• No new sites of disease.
• Improvement of cytopenias.
• Decrease of infiltration and improvement of haemopoietic
reserve at BM biopsy.
No response
• <10% improvement on the disease manifestations.
Progression
• >50% of measurable signs of the disease from nadir.
Relapse
• re-appearance of any measurable sign of the disease.
1.3.5 FOLLOW-UP/MONITORING
For asymptomatic patients with disseminated MZL, we
recommend physical examination, blood counts, and
biochemistry every 6 months. The interval between controls
should be shortened in case of increasing splenomegaly and/or
occurrence of cytopenia(s). A CT scan or bone marrow biopsy
is not indicated unless signs of disease progression are
identified. For treated patients, we recommend to check blood
counts and laboratory work-up every 4–6 weeks during the
first 3 months, and every 6 months thereafter.
2. Mantle cell lymphoma
2.1. Diagnosis and molecular risk factors
Diagnosis
The diagnosis of MCL is established according to the criteria
of the WHO classification of haematological neoplasms and
requires the detection of cyclin D1 expression or the t(11;14)
translocation in the context of a mature B-cell proliferation [1].
The diagnosis of MCL, as in other lymphomas should be
confirmed by review by an expert haematopathologist.
Most tumours have a classic morphology of small-medium
sized cells with irregular nuclei, dense chromatin, and
unapparent nucleoli. However, the tumour cells may present
with a spectrum of morphological variants, including small
round, marginal zone-like, pleomorphic, and blastoid cells that
may raise some difficulties in the differential diagnosis with
chronic lymphocytic leukaemia, MZLs, large B-cell
lymphomas, or blastic haematological proliferations.
Annals of Oncology special article
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The tumour cells are clonal mature B cells that express
strong immunoglobulin M/immunoglobulin D and frequently
CD5 whereas CD23, CD10, and BCL6 are usually negative.
Although the phenotype may be suggestive of the disease the
confirmation of the diagnosis requires the demonstration of the
cyclin D1 expression or the presence of the t(11;14)
translocation because a number of cases may have atypical
phenotypes such as CD5 negativity or expression of CD10
[34, 35]. SOX11, a transcription factor involved in neural
development, has been recently identified as a reliable marker
of MCL since it is expressed in ∼90% of MCL, and it is
negative in virtually all B-cell lymphoid neoplasms with the
exception of 30% of Burkitt lymphomas and lymphoblastic
lymphomas [36, 37].
The presence of cyclin D1 positive B cells in the mantle zone
of an otherwise reactive lymphoid tissue may be found
incidentally in asymptomatic individuals or in lymph nodes
biopsied for other pathologies. These lesions should not be
considered and treated as overt lymphomas and they should be
managed with caution.
A cyclin D1-negative variant of MCL has been recognized
[38]. These cases have a similar morphology and phenotype but
lack the expression of cyclin D1 and the t(11;14) translocation.
These cases have a similar profile of gene expression and
genomic alterations than conventional cyclin D1-positive MCL
but the number of cases examined is still very limited [38–40].
SOX11 is expressed in cyclin D1 MCL, and therefore, it may be
a reliable marker to identify this variant [36].
2.1 Consensus statement
Although the phenotype may be suggestive of the disease the
confirmation of the diagnosis requires the demonstration of the
cyclin D1 expression or the presence of the t(11;14) translocation.
Level of evidence: III
Grade of recommendation: A
2.2 Prognosis
The clinical evolution of MCL is very variable with some
patients following a rapid course whereas others may have a
relatively indolent disease. Many studies have analysed the
clinical and biological prognostic parameters in MCL (See
review in [41]). The most consistent biological prognostic
parameter is the proliferative activity of the tumours. All
different measurements of proliferation such as the mitotic
index, Ki-67 index, gene expression proliferation signature, or
other proliferation-related markers have revealed their
prognostic value in patients with MCL with different
discriminative power [41]. Most other biological parameters
with prognostic value are usually related to proliferation and
lose their independent significance in multivariate analysis
when compared with proliferation, or have not been properly
evaluated in comparison to proliferation [41–43]. The
evaluation of the Ki-67 proliferative antigen is the most
applicable and discriminative method to evaluate proliferation
[44]. However, the major limitation to use this marker in
clinical practice is the difficulties in the reproducibility of
quantitative scores among different pathologists [45].
In clinical studies, the Ki67 index should be evaluated
consistently by the same observer using recommended
evaluating guidelines [44].
TP53 mutations have been confirmed to be of prognostic
significance in large series of patients. Some studies have
reported molecular and genetic alterations that maintain their
prognostic prediction independently of the proliferation of the
tumours. The quantitative evaluation of the expression of small
panels of genes, including MYC seems to improve the
prognostic value of the tumour proliferation [46, 47]. Similarly,
the concomitant inactivation of the two regulatory pathways
INK4a/CDK4 and ARF/p53 in MCL was associated with a
poor survival that was independent of Ki-67 proliferation index
[48]. Interestingly, the impact of the chromosome 3q gains and
9q losses on survival is independent of the microarray
proliferation signature [39]. However, these results have not
been confirmed by independent studies in larger series of
patients and therefore are not recommended for clinical use.
2.2 Consensus statement
Ki67 staining is recommended in the routine practice as a
prognostic indicator but the results should be evaluated with
caution particularly when comparing studies from different
institutions.
Level of evidence: I
Grade of recommendation: A
2.3 Indolent forms of mantle cell lymphoma
Most patients with MCL follow an aggressive clinical course.
However, some studies indicate that a subset of patients may
have a more indolent evolution. Studies of prognostic factors in
MCL have indicated that tumours with very low proliferation
fraction, limited-stage, or a mantle zone pattern may have a
significant better prognosis with longer survival than the global
series of patients [49, 50]. In addition, some observations
recognized a subgroup of patients with MCL with an indolent
behaviour that presented with a non-nodal disease, frequent
splenomegaly, and a leukemic phase. These cases seem to have
also different biological features including a different gene
expression signature that includes SOX11 [35, 51]. This
biomarker is positive in 90% of the conventional MCL and
negative in a subset of MCL with a non-nodal disease and
indolent clinical behaviour [35, 52]. SOX11-negative MCL with
nodal disease and TP53 mutations may correspond to
transformed cases and have an aggressive clinical evolution.
However, the clinical and biological studies on this form of
MCL are still limited. Further studies are needed to clarify
these issues. As there are no markers to definitely predict
indolent behaviour, a course of watch and wait under close
observation may be appropriate in individual suspected cases
with low tumour burden.
2.3 Consensus statement
At the present moment, it is not possible to establish definitive
recommendations on the diagnosis and management of
indolent MCL.
Level of evidence: IV
Grade of recommendation: C
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2.4 Clinical risk factors
Since its histological identification, MCL has always been
considered as a disease with a uniformly poor outcome [1, 53,
54]. This notion together with its rarity has limited efforts
aimed at identifying prognostic parameters in this tumour up
to the end of the millennium. With the introduction of more
effective treatments, the prognosis of MCL has improved not
only in terms of PFS but also in terms of OS. The study from
Herrmann et al. [55] has shown that patients treated in clinical
trials between 1996 and 2004 had a 5-year OS of 47%
compared with 22% observed in previous studies.
The improved outcome and the perception that the clinical
history of MCL was as heterogeneous as that of most
lymphoproliferative disorders led to increased efforts aiming at
investigating histological, clinical, and biological outcome
predictors. Although several candidate prognostic markers have
been investigated, only the following have been adequately
addressed to warrant consideration in the clinical setting:
• histological predictors, particularly proliferative index
[35, 56]
• the MCL International Prognostic Index (MIPI) [57]
• minimal residual disease (MRD) [58]
Outcome prediction based on simple clinical scores proved
highly successful in disparate clinical settings, including FL and
DLBCL) [59–61]. Some studies have addressed the predictive
value in MCL of prognostic scores ‘imported’ from other
lymphomas but prognostic discrimination was sub-optimal
[50, 62–64]. This led to the development of the MIPI in 2008
[57]. This score takes into account four parameters (age,
performance status, lactate dehydrogenase, and leukocyte
count). It was originally devised using a mathematical
algorithm to balance the weight of different predictors, but
proved effective also in its simplified version, where all
predictors were categorized [57, 65]. The MIPI score allows to
discriminate three prognostic subgroups: median OS was not
reached in the low risk group with a 5-year OS of 60%, and it
was 51 and 29 months in the intermediate risk group and the
high-risk group, respectively. The MIPI score is highly
applicable, showed remarkable reliability and complemented
histological and PCR-based predictors [57, 58]. Moreover,
several independent studies succeeded in validating the MIPI
score in different clinical and therapeutic contexts, with the
only exceptions observed in underpowered single-institution
series [65–71] (supplementary Table S1, available at Annals of
Oncology online).
PCR-based evaluation of MRD has also shown remarkable
predictive value in MCL. Since the 1990s, MRD has been used
in several studies documenting the improved performances of
rituximab and Ara-C-based regimens compared with less
innovative approaches [72–77] (supplementary Table S2,
available at Annals of Oncology online). The first paper clearly
documenting the prognostic value of MRD in MCL was a
retrospective analysis from Pott et al. [58] mainly focusing on
young patients undergoing autologous transplantation [78].
Superior evidence on the predictive value of MRD was
provided by the prospective MRD analysis of two European
MCL network trials. In this analysis, MRD proved as a
powerful independent outcome predictor together with MIPI.
Most notably the predictive value of MRD detection was
observed both in young patients treated intensively and in
elderly patients receiving conventional treatment and
maintenance either with interferon-α (IFN-α) or rituximab.
MRD detection by PCR is not devoid of costs and is usually
carried out in centralized laboratories with considerable ‘know-
how’ in the field. These aspects still represent limitations to a
widespread use of MRD results in the clinical practice. On the
other hand, considerable effort is ongoing with the aim of
developing standardized rules that will ensure greater
applicability and reproducibility of results [79]. Moreover,
further validation of the results from Pott et al. [58] will be
necessary from independent patient series. Several ongoing
phase III clinical studies are investigating MRD determination
and results will be available in the next few years.
Based on the reliability of MRD detection in MCL, tailored
treatment based on PCR results has been employed in at least
two reports [80–82] (supplementary Table S3, available at
Annals of Oncology online). In these studies, molecular relapses
of autografted MCL patients were treated with rituximab. This
led to re-induction of molecular remission in the vast majority
of patients. In particular, based on the larger Nordic study, this
seemed to provide clinical benefit to patients undergoing pre-
emptive treatment [81, 82]. These results are of great
importance as they might provide an effective way to deliver
additional tailored treatment only in subjects who actually
require it. However, the broad applicability of such approaches
still need to be proven, and their efficacy need to be formally
assessed in phase III trials. In general, there is some evidence
that risk-adapted treatment is feasible and useful, but should
not be used in the clinical practice. Its optimal use should be
investigated in clinical trials.
2.4 Consensus statement
MIPI is highly applicable and has been validated in most
independent series. Is the use should be encouraged in the
clinical practice.
Level of evidence: I
Grade of recommendation: A
2.5 Consensus statement
MRD detection by PCR is a powerful independent predictor.
However, because of limitations of applicability, reproducibility
and validation its use is not recommended in routine clinical
practice outside of clinical trials.
Level of evidence: IV
Grade of recommendation: C
2.5. Elderly patients
Treatment of elderly patients with MCL is a major challenge.
With a median age of 60–65 years at presentation, more than
half of the patients with newly diagnosed MCL fall into the
category ‘elderly’. Whereas the prognosis of younger patients
(e.g. aged <65 years) has largely improved with the
introduction of high-dose cytarabine followed by upfront
autologous stem-cell transplantation (SCT), these therapeutic
options are thus far considered not feasible for the higher age
group.
Annals of Oncology special article
Volume 24 | No. 4 | April 2013 doi:10.1093/annonc/mds643 | 
 by guest on N
ovem
ber 21, 2016
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
Monitoring for MRD has shown that patients—independent
of age—who have obtained a complete molecular response can
enjoy longstanding event-free survival [58]. Consequently, it
seems important to obtain a complete response (CR), not only
for younger patients, but also for the elderly ones. Treatment
of elderly patients requires careful balancing between toxicity
and efficacy. A good performance status and the absence of
co-morbidity are required for any treatment aiming at
complete remission. Therefore, a common approach consists of
an upfront stratification of patients into elderly fit and elderly
frail categories [83].
2.5.1 Elderly fit patients
A randomized, controlled trial comparing combination
chemotherapy with cyclophosphamide, doxorubicin,
vincristine and prednisone (CHOP) versus R-CHOP showed
that R-CHOP was significantly superior to CHOP in terms of
overall response rate (ORR; 94% versus 75%; P = 0.0054),
complete remission rate (34% versus 7%; P = 0.00024), and the
time to treatment failure (TTF; median, 21 versus 14 months;
P = 0.0131). No differences were observed for PFS [84].
However, a meta-analysis comprising three randomized,
controlled trials involving 260 patients with MCL summarized
that the addition of rituximab improved OS in patients with
MCL (HR for mortality 0.60; 95% CI 0.37–0.98) [85, 86].
Only one randomized, controlled trial has been carried out for
elderly patients with MCL comparing R-CHOP with rituximab,
fludarabine, cyclophosphamide (R-FC), followed by a second
randomization focusing on maintenance therapy [87]. Of 560
patients, 457 were assessable for response to induction. Whereas
CR rates after R-FC and R-CHOP were similar (38% versus
34% CR), the ORR was lower after R-FC (78% versus 87%;
P = 0.0508). Progressive disease was more frequent during R-FC
(15% versus 5%). The median OS was significantly inferior after
R-FC (40 versus 64 months; P = 0.0072). More patients in the
R-FC arm died due to lymphoma or to infections.
In the above-mentioned RCT, in addition to less efficacy, it
appeared that haematologic grade 3–4 toxic effects were more
frequent during R-FC, especially thrombocytopenia (40%
versus 17%). This toxicity hampered continuation of treatment
and start of maintenance therapy. Thus, the use of upfront
R-FC should be discouraged. In contrast a recent trial has
suggested that R-bendamustine seem to be as effective, but is
better tolerated than R-CHOP [88].
In the above-mentioned RCT, 310 patients underwent the
second randomization focusing on maintenance therapy.
Rituximab maintenance almost doubled the remission duration
compared with IFN-α (at 4 years, 57% versus 26% in
remission; HR 0.54, 95% CI 0.35–0.87; P = 0.0109). OS did not
differ between both maintenance arms (P = 0.17). However, the
sub-cohort of R-CHOP-treated patients showed a significant
advantage after rituximab maintenance (4-year OS 87% versus
57% after IFN; P = 0.0061).
2.5.2 Elderly frail patients
Induction therapy could consist of mild chemo-
immunotherapy, for example chlorambucil combined with
rituximab [89, 90]. Single-agent therapy with rituximab (four
gifts at weekly intervals) for treatment-naive patients is not
recommended as only very low overall responses of 27% with
3% complete remissions have been obtained [91]. Thus,
treatment of elderly frail patients should aim at palliation
knowing that cure will not be obtained.
2.6 Consensus statement
Rituximab should be part of any induction chemotherapy
regimen.
Level of evidence: I
Grade of recommendation: A
2.7 Consensus statement
Rituximab maintenance (one dose every 2 months until
progression) should be offered to all patients responding upon
R-chemotherapy, especially R-CHOP induction.
Level of evidence: I
Grade of recommendation: A
2.6 Younger patients with MCL
Retrospective analysis of MD Anderson experience using
intensive induction regimen in MCL has shown that
rituximab increases response rate and PFS [92]. In addition,
a randomized, controlled trial comparing CHOP versus
R-CHOP showed that R-CHOP was significantly superior to
CHOP in terms of ORR (P = 0.0054), complete remission
rate (P = 0.00024), and TTF (P = 0.0131) [84]. A meta-
analysis comprising three randomized, controlled trials
involving 260 patients with MCL summarized that the
addition of rituximab improved OS in patients with MCL
(HR for mortality 0.60) [85].
Several phase II studies have suggested that incorporation of
high-dose Ara-C in the induction chemotherapy regimen
before autologous transplantation (ASCT) increase the CR rate
and PFS [76, 94–96]. In a recent trial, comparing six courses of
CHOP plus rituximab followed by ASCT versus alternating
courses of 3 × CHOP and 3 × DHAP plus rituximab followed
by a high-dose cytarabine-containing myeloablative regimen
experienced a significantly longer TTF in the experimental arm
(P = 0.0384) mainly due to a lower number of relapses, whereas
the rate of ASCT-related deaths was similar in both arms, but
OS was similar in both arms [97]. Impact of cytarabine on the
PFS rate seems to be linked with the quality of molecular
remission, which was significantly higher after induction. Thus,
the results of this trial demonstrate definitively the value of
adding high-dose cytarabine in the induction regimen of MCL,
and suggest this new standard of treatment in young patients
[97, 98].
Patients under 60–65 years are usually considered as young
patients and may benefit of intensive therapies. However, this
paradigm may change since a recent publication show that up
to 70 years old, fit patients with no co-morbidity may benefit
from intensive therapies as do young patients with similar
efficacy and safety [99]. The landmark trial of the EMCL is the
only randomized study comparing ASCT following a
conditioning regimen with total body irradiation (TBI) and
high-dose cyclophosphamide to maintenance therapy with
IFN-α [93]. Patients responder to CHOP-like induction have a
longer PFS in the ASCT arm (median, 39 versus 17 months,
P = 0.0108). In addition, after long-term follow-up OS is
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superior in the ASCT arm. This benefit is detectable in the
low- and intermediate risk patients according to MIPI, who
represent the vast majority of younger patients with MCL.
Other phase II have shown that ASCT improves PFS in MCL
[94–96]. Thus, ASCT should be carried out in first-line therapy
in young patients.
Currently, conditioning regimen used in MCL are those used
in other lymphoma subtypes. The benefit effect of additional
rituximab for in vivo purging has not been demonstrated in
randomized studies and/or in meta-analysis. Due to the
radiosensitivity of MCL cell lines, the role of TBI remains an
important question. A small retrospective study have suggested
that patients who did receive a conditioning regimen with TBI,
when compared with those that received BEAM did better with
a significant improvement of 4-year disease-free survival (DFS;
71% versus 0%) and OS (89% versus 60%) [100]. An EBMT
retrospective study showed that TBI may benefit only for the
group of patients that are in partial response (PR) but not in
CR [overall response (OR) 0.52 versus OR 1.03 for relapse
incidence] but with no significant improvement of OS [101].
Taken together, these studies suggest that TBI is not
mandatory in patients in first CR but should be discussed in
patients in PR. Conditioning regimen using
radioimmunoconjugate are currently investigated in the Nordic
MCL-3 study in patients who are not achieving CR after
induction chemotherapy, but currently there is no clear
evidence that they improve outcome of MCL (reviewed in
[54]).
Another dose-intensified approach (Hyper-CVAD) with
alternating CHOP-like and high-dose methotrexate/cytarabine
cycles also showed very high response rates in a mono-centre
phase II study. However, these excellent results could not be
replicated in a multicentre approach and were never tested in a
randomized, phase III trial. Moreover, this regimen is
hampered by a significant therapy-associated toxicity, which
led to a high drop-up rate in the multicenter trial.
Difficulties to obtain a plateau with conventional
chemotherapy regimens as well as the importance of clearing
MRD raise the question of maintenance therapy in MCL.
Rituximab maintenance after R-CHOP induction should be
considered the new standard for elderly patients with MCL, to
which new regimens should be compared. However, these data
should be confirmed for the young patients in the context of
intensive chemotherapy and ASCT. This question is currently
addressed in the Lyma trial, in which maintenance by
rituximab versus no maintenance after treatment by four
R-DHAP followed by ASCT is randomized. However, data
generated are insufficient to establish treatment guidelines but
encourage further investigations in this direction. Thus, so far,
maintenance therapy with rituximab cannot be uniformly
recommended in young patients with MCL after ASCT.
The first randomized studies documenting molecular
response after combined immunochemotherapy in a significant
fraction of patients were the trials of the European MCL
network. These trials investigated different
immunochemotherapy protocols followed by ASCT in younger
patients or maintenance treatment in patients >65 years or
ineligible for ASCT [58]. Molecular response resulted in a
significantly improved response duration (P < 0.0043) and
emerged as an independent prognostic factor for response
duration (P < 0.027). Molecular response was highly predictive
for prolonged response duration independent of clinical
response (P < 0.0015). Thus, in addition to clinical CR,
molecular studies should be carried out and negativity of MRD
assessed by RQ-PCR should be a goal to achieve.
Techniques of molecular biology allow detecting sub-clinical
relapses. In 2006, Ladetto et al. [80] report four patients treated
in first molecular relapsed after ASCT by 4–6 rituximab
perfusion. All patients obtain a new molecular remission. After
3–32 months of follow-up, one patient developed a new
relapse, again sensitive to rituximab. Andersen et al. published
a phase II on the use of rituximab in molecular relapse after
ASCT [81, 82]. Among 160 patients, 26 patients received pre-
emptive rituximab, allowing a new molecular remission in 92%
of patients. After this treatment the median molecular DFS was
1.5 years and the median clinical-relapse-free survival was 3.7
years. These results are promising but there’s a lack of
randomized trials to compare this attitude to the conventional
treatment.
2.8 Consensus statement
Rituximab should be used in induction chemotherapy regimen
in MCL.
Level of evidence: I
Grade of recommendation: A
2.9 Consensus statement
Induction with high-dose cytarabine regimen is superior to
R-CHOP in young patients with MCL.
Level of evidence: I
Grade of recommendation: B
2.10 Consensus statement
Autologous stem transplantation should be carried out in first-
line therapy.
Level of evidence: I
Grade of recommendation: B
2.11. Consensus statement
No conditioning regimen has shown a clear superiority;
However, TBI may improve PFS in patients in PR after
induction.
Level of evidence: IV
Grade of recommendation: C
2.12 Consensus statement
Therapy of MRD driven strategies cannot yet be recommended
outside of clinical trials.
Level of evidence: III
Grade of recommendation: C
2.7 Molecular approaches in relapsed MCL
During the last decade, important insights have been gained
into the molecular lymphomagenesis of MCL, and based on
the identified signal pathways, numerous antibody-based and
other targeted approaches are currently being explored in MCL
[49, 102]. Especially, mTOR inhibitors, proteasome inhibitors,
and immune-modulatory molecules (IMIDs) have shown high
efficacy in relapsed MCL. In addition, the B-cell receptor has
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been recently identified as a crucial signal pathway in MCL,
and small molecules targeting this pathway have achieved high
response rates in relapsed disease even as oral monotherapy
(PCI, Cal-101) [103]. Thus, due to the only short-term
remissions after conventional chemotherapy, such molecular
approaches have been already generally recommended in
relapsed MCL [54].
Temsirolimus
The mTOR inhibitor temsirolimus has achieved response rates
of 38%–41% in two phase II studies and even up to 63% in
combination with rituximab [104, 105]. In the only
randomized trial carried out so far, temsirolimus achieved a
significant higher response rate and PFS to investigators choice
of monotherapy (mostly purine analoga, gemcitabine).
Accordingly, temsirolimus is the only biological registered for
relapsed MCL in EU, but response was only 22% in a high-risk
patient population (Table 3) [106]. Thus, future studies will
focus on combined approaches to further explore the benefits
of mTOR inhibition.
2.13 Consensus statement
Temsirolimus should be considered in advanced relapses
(greater than second line). The recommended dose
monotherapy is 75 mg, whereas data on the 175-mg induction
dose are inconclusive.
Level of evidence: II
Grade of recommendation: B
Temsirolimus may be especially considered in relapsed non-fit
patients.
Level of evidence: IV
Grade of recommendation: C
Bortezomib
The proteasome inhibitor has achieved response rates of
29%–46% in numerous phase II studies including a large
international trial with >150 patients with relapsed MCL [107].
Accordingly, bortezomib monotherapy is registered in relapsed
MCL in the United States. However, data from randomized
trials are missing. Toxicity is reasonable, but median PFS is
only in the range of 6–9 months. Current trials have reported
long-lasting remissions in combination with
immunochemotherapy, especially cytarabine-containing
regimens [108, 109].
Lenalidomide
The second-generation immune modulatory compound
lenalidomide has achieved response rates of 38%–50% in
various phase II studies including a large international trial
with 57 patients with relapsed MCL but data from randomized
trials are missing [110]. Toxicity seems to be favourable besides
some moderate myelotoxicity, and median PFS under
continuous medication may extend 6–9 months. Current trials
investigate monotherapy or consolidation after
immunochemotherapy induction as explored in multiple
myeloma.
2.14 Consensus statement
Bortezomib and lenalidomide may be considered in advanced
relapses (greater than second line)
Level of evidence: III
Grade of recommendation: B
2.8 Allogeneic stem-cell transplantation in MCL
Up to now, the question of allogeneic SCT (allo-SCT) in MCL
has only been addressed in monocentric (including several
reports from the same institution) or registry based
retrospective studies but no phase III or prospective trials have
been carried out. Thus, the role and place of allo-SCT in MCL
according to evidence-based medicine remains a challenging
issue.
In the late 1990s and early 2000s, the first experiences of
allo-SCT in patients with relapsed or refractory MCL used
myeloablative-conditioning regimens [111–118]. Patient age
and allo-SCT toxicity and efficiency were major concerns.
These studies covered only small numbers of highly selected
patients with MCL with median ages <50 years at the time of
allo-SCT [99, 115–126] (Table 4). At D100 after allo-SCT,
toxicity-related mortality (TRM) was between 0% and 32%
[111–118]. The 3-year PFS rates were 41% and 55%,
respectively, in Kasamon’s and Khouri’s reports [114, 115].
More recently, extended use of reduced-intensity
conditioning regimen (RIC-allo) improved the feasibility of
allogeneic transplant in patients with MCL aged >50 years
[119–126]. Further investigations have dealt with RIC-allo in
patients with MCL, and the number of patients has increased
(with a median age at transplant >55 years in some studies)
(Table 5). However, the result of RIC-allo in MCL varies much
Table 3. Moleculars in mantle cell lymphoma
References Regimen/single dose Prior lines (median) Pat no OR/CR Median TTP/PFS
103 Temsirolimus 250 mg 3 35 38/3 6.5 months
Temsirolimus 25 mg 4 29 41/4 6 months
104 Temsirolimus 25 mg, rituximab 2.5 71 59/19 9.7 months
105 Temsirolimus 175/75 mg 3.5 54 22/– 4.8 months
106 Bortezomib 1.3 mg/m2 1 155 32/8 6.7 months
107 Bortezomib 1.5 mg/m2*, R-HAD 4 8 50/25 5.5 months
108 Bortezomib 1.3 mg/m2, R-CHOP 0 36 91/72 64% (2 years)
109 Lenalidomide 25 mg 3 57 42/21 5.7 months
102 PCI 3265 560 mg 2 51 69/16 na
*Phase III trial.
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from one study to the other. TRM at 1 year varies between 9%
to 46%. Two-year OS varies between 12.8% to 65% and 2-year
PFS from 0% to 60% (Table 5). Prognostic factors regarding
OS, PFS, risk of relapse, and TRM also vary. The nature of
conditioning regimen, disease status at transplantation, and the
monocentric or multicentric nature of the reports partially
explains the discrepancies. Almost all authors highlight the fact
that RIC-allo can provide patients with refractory/relapsed
MCL with long-term DFS, although risk of relapse is higher
for patients with transplanted MCL than for other NHL
patients. Interestingly, conditioning regimens with T-depletion
seem to increase relapse.
Although most authors agree that RIC-allo may be curative
for some patients with MCL, the paucity of literature and the
relatively small number of patients per study do not allow for
any strong recommendations for allo-SCT in MCL.
Is there enough evidence of graft-versus-MCL effect to support
allo-SCT in MCL?
GVD-MCL is documented by several reports and supported
by the following:
• long-term CR in refractory/relapsed patients is achievable
after allo-SCT,
• relapsed patients can reach prolonged CR, including
molecular CR, after allo-SCT, and donor lymphocyte
infusions (DLIs),
• the risk of relapse increases for transplanted patients
undergoing T-cell depletion, which abrogates the effect of
GVD,
• withdrawal of immunosuppression can reduce tumour
progression.
When is allo-SCT to be used in MCL?
Reports describe allo-SCT carried out in patients with
relapse or refractory MCL. It has never been proved that allo-
SCT is superior to auto-SCT, neither upfront, nor at the time
of relapse. Auto-SCT and intensive chemotherapy regimens, e.
g. hyper-CVAD, upfront have been shown to give lower TRM
than allo-SCT.
2.15 Consensus statement
Possible GVD-MCL supports the use of allo-SCT in MCL
Level of evidence: III
Grade of recommendation: C
2.16 Consensus statement
Allo-SCT is not recommended upfront in MCL but may be
considered for fit patients with MCL experiencing either
relapse or refractory disease after appropriate line(s) of
treatment.
Level of evidence: III
Grade of recommendation: C
3. Peripheral T-cell lymphoma
3.1 Diagnostic procedures and tools
According to the 4th edition of the WHO Classification of
Tumours of Haematopoietic and Lymphoid Tissues, peripheral
natural killer (NK)/TCLs account for about 12% of lymphoid
malignancies (supplementary Table S4, available at Annals of
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Table 5. Results from published reports about RIC-allo-SCT in MCL
References Year N Median age (years) Disease status at the time
of transplantation
Median FU PFS or EFS OS TRM/toxicity
125 2002 22 52 (44–57) Chemosensitive 73%
Chemoresistant 14%
and unknown
283 days, not only
patients with MCL
48.2% (1 year)
0% (2 years)
12.8% (2 years) 13.6%, D100
46% (1 year)
82% (2 years)
122 2004 33 53.5 (32.6–69.6) CR, n = 13
PR, n = 13
24.6 months 60% (2 years) 65% (2 years) 24% (2 years)
119 2010 70 52.2 (34.7–68.8) CR1 30%
≥CR2 21.5%
PR1 13%
≥PR2 17.5%
37 months 14% (5 years) 37% (5 years)
60% at 3 years for patients
in CR at transplantation
11%, D100, NRM
18% (1 year)
21% (5 years)
120 2007 14 One CR
PR, n = 7
Refractory, n = 6
33 months, not only
patients with MCL
33% (3 years) 45% (3 years) 32% (3 years), NRM
121 2003 18 56.5 (46–64) CR 44%
PR 44%
SD 12%
33 months, not only
patients with MCL
33% (3 years) 45% (3 years) 0%, D100
123 2004 10 48 (18–73), not only
patients with MCL
CR 40%
PR 50%
Refractory 10%
26 months 82% (3 years) 85.5% (3 years) 20% (3 years), NRM
118 2008 15 51 (34–64), all patients All patients: 27% in CR
and 49% in PR
36 months, not only
patients with MCL
50% (3 years) 60% (3 years) 37% (3 years), NRM
91 2009 35 58 (43–68) Chemosensitive 83% 26 months, not only
patients with MCL
22% (3 years) 40% (3 years) 0% (3 months) and
9% (1 year)
124 2002 6 2 years Failure-free survival: 60% 77% for all patients
FU, follow-up; PFS, progression-free survival; EFS, event-free survival; TRM, toxicity-related mortality; NRM, non-relapse mortality; CR, complete response; PR, partial response.
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Oncology online) [1]. They stem from NK- or γδ T cells that take
part in the innate immune response or, more frequently, from
different subsets of αβ T lymphocytes that belong to the adaptive
immune reaction. Basically, these subsets correspond to naïve,
effector, memory, and follicular T helper (FTH) cells. NK/TCLs
include 22 entities (listed in Table S4, available at Annals of
Oncology online, with their acronyms), 4 of which provisional.
They can be recorded in every part of the World, although same
varieties occur endemically (i.e. ATLL in Southern Japan and
Caribbean basin, ENKTL/NT in Far East and native Americans,
EATL in UK and Scandinavian countries).
In principle, their diagnosis should always be made by an
expert haematopathologist and relies on a tissue bioptic
specimen, unless the process is leukaemic. Cytology on fluid
aspirates ought be avoided or considered insufficient.
According to the criteria of the WHO Classification, the
identification of NK/TCL as well as the distinction among
different entities requires the integration of clinical picture,
morphology, immunohistochemistry, FC, cytogenetics, and
molecular biology [1].
While in B-cell lymphomas the monotypic restriction of
κ and λ Ig light chains represents a surrogate of monoclonality,
in TCLs the stains for CD4 and CD8 do not play the same
role: in fact, they can turn double negative or double positive
in a significant proportion of cases [127]. Thus, the indication
of the neoplastic nature of a given T-cell population is based
on morphology as well as the lack of one or more of the T-cell-
associated antigens, this implying the application of a panel
from CD2 to CD8. On this respect, CD5 and CD7 are the most
frequently defective markers [1, 127]. In particular, the
aberrant phenotypic profile, possibly integrated by the
detection of clonal re-arrangement of the genes encoding for
the T-cell receptor by the BIOMED-2 approach, is pivotal for
the distinction between partial lymph node involvement by
TCL and paracortical T-cell hyperplasia [128].
Several markers can be used for the identification of the
T-cell subset, which the tumour is related to. Thus, TIA1,
granzyme B, and perforin stand for a cytotoxic profile and are
usefully applied to define a more aggressive subset of TCL/
NOS or to construct diagnostic profiles [see, for instance
HSTL, CD8+ PCAECTL or anaplastic large cell lymphoma
(ALCL), both ALK+ and ALK−]. CD10, Bcl6, CXCL13, PD1,
SAP, ICOS, and CCR5 are characteristically carried by FTH
cells [1, 129]. Such markers can be used for the identification
of neoplasms stemming from this compartment. However, in
doing this, one should consider that (i) at least three of them
must be detected to ascertain an FTH derivation, because a
single positivity can the result of cell plasticity;[130] (ii) their
expression is not restricted to AITL, as there is now evidence
that the same phenotype can be found also in tumours of the
NOS type that like the former consist of clear cells [131].
Therefore, the diagnosis of AITL should be based on the
characteristic clinical picture, hyperplasia of CD21+ follicular
dendritic cells (FDC), arborizing high endothelial venules and
B-cell component in part represented by EBV-infected blasts,
besides the expression of FTH-related markers.
FoxP3 is carried by regulatory T cells: it is typically observed
in the HTLV1-associated ATLL along with positivities for
CD25 and CCR4 and negativity for CD7 [1]. CD16, CD56,
and CD57 in variable combinations and often in association
with cytotoxic markers assist in diagnosing T-LGL, NK-CLPD,
NK-AL, ENKTCL/NT, type II EATL, and HSTL [1]. Notably,
true NK cases show intra-cytoplasmic positivity for the ɛ-chain
of CD3 in contrast to TCLs that carry CD3 positivity at the
cytoplasmic membrane level [1]. CD56 does also concur to the
differentiation between γδ+/CD8+ PCAECTL and αβ+/
SCPLTL that turn, respectively, positive and negative [1]. CD30
plays a basic role in the recognition of ALCLs, CD30+ CTLPD,
and the rare CD30+ TCLs/NOS, provided with a very poor
behaviour [132]. ALCLs that are systematically PAX5−,
frequently EMA+ and in one-third of the cases CD45−, are
further distinguished in ALK+ and ALK− depending on the
occurrence or not of the t(2;5) translocation and variants [1].
These chromosomal aberrations lead to the formation of
hybrid genes and fusion proteins involving the anaplastic
large-cell lymphoma kinase (ALK) [1]. The latter can be
revealed by specific antibodies that produce variable positivities
(nuclear and cytoplasmic, intra-cytoplasmic or bound to the
cytoplasmic membrane) depending on the type of fusion gene.
The anomalous expression of ALK—that is provided with
oncogenic properties—does not occur in ALK− ALCL. The
latter is morphologically and phenotypically indistinguishable
from the ALK+ form and this might reflect the occurrence of
genetic aberrations other than t(2;5) and variants but
producing the same downstream effects. The distinction
between ALK+ and ALK− ALCLs is of practical
relevance, since the former behave much better than the
latter [1, 133].
In this setting, additional markers that can contribute to the
diagnosis of NK/TCLs, are CD20, PAX5, CD21, CD68, and
MIB1. CD20 and PAX5 allow the identification of B-cell
components as can help in distinguishing ALK− ALCL from
morphologically aggressive classical Hodgkin lymphoma
(PAX5+); CD21 highlights the content of FDCs in AITL;
CD68 reveals the histiocytic component that can at times
obscure the neoplastic one (e.g. lympho-epithelioid TCL or
Lennert’s lymphoma and ALCL, lympho-histiocytic variant).
The Ki-67 marking does represent another relevant tool, being
potentially provided of prognostic value, as suggested by gene
expression profiling data and the inclusion in a clinico-
pathologic score [129, 134]. In particular, the latter
corresponds to a modified PIT in which bone-marrow
involvement is substituted by a Ki-67 rate higher than 80%
[135].
Finally, the search for EBV, especially by EBER in situ
hybridization, has an important role in PNK/TCL diagnosing.
Some entities (e.g. EBV+ ANKL, EBV+ LPD-C, and ENKTL/
NT) as well as a variable proportion of TCLs/NOS, in fact,
show positivity of neoplastic cells for EBV [1]. Notably, all
these neoplasms are characterized by a very aggressive clinical
behaviour.
3.1 Consensus statement
The diagnosis of peripheral TCL requires the review by an
experienced haematopathologist, the panel of mandatory
markers are listed in Table 6. In the light of that fact that
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conventional microscopy may be elusive, a cytologic spectrum
being commonly seen within each category.
Level of evidence: IV
Grade of recommendation: A
3.2 Prognostic models
In the literature published so far, the 5-year OS of TCL
patients treated with doxorubicin-based chemotherapy ranges
between 25% and 45% [134].
Different prognostic systems have been proposed.
Morphology does not always correlate with outcome, and the
significance of the international prognostic index (IPI) is
controversial, although most investigators agree on its
relevance [136, 137]. Moreover, different from other prognostic
scores, IPI seems to predict treatment outcome in all TCL
subtypes, included NK/T-cell nasal-type subtype and ATLL
[138, 139]. Later on, in 2004, a clinical score called peripheral
T-cell index (PIT) has been proposed to improve prognostic
stratification of TCL/U patients [135]. As in IPI age,
performance status and LDH were confirmed as prognostic
factors but bone-marrow involvement was more relevant then
advanced stage or extra-nodal sites. Recently, a modified
version of this prognostic model has been proposed, where
bone marrow attainment was substituted with Ki-67 (mPIT)
[127]. This proposal has been made with the aim of
substituting bone marrow involvement by lymphoma with a
more reproducible, operator-independent variable, such as the
mitotic Index assessed by immunoperoxydase. The
International T-cell Project has been risen to retrospectively
evaluate the prognosis of TCL in a cohort of patients in whom
the diagnosis was centrally reviewed: a new model has been
proposed incorporating age, performance status and platelets
[140]. However, the value of these models is limited since the
5-years OS ranges between 37% and 5% for the low and high-
risk classes, respectively. In patients with TCL treated with
alemtuzumab, CD 52 expression has been evaluated [141].
Although preliminary studies have been done in very limited
series of patients, CD 52 expression did not seemed to
correlate with treatment outcome [142].
3.2 Consensus statement
IPI should be applied in peripheral TCL
Level of evidence: IV
Grade of recommendation: C
3.3 First-line treatment
In first-line, as well as in second-line treatment patients should
be enrolled, whenever possible and feasible, in clinical trials.
First-line treatment of all TCL subtypes but NK/TCL, nasal
type, should be based on Anthracycline-containing regimens
such as CHOP/CHOEP and CHOP-like regimens. An
exception to this assumption could probably made for
enteropathy-associated T-cell lymphoma (EATL) that has been
treated with a specific regimen according to the Scottish
Lymphoma Group.
3.3 Consensus statement
For NK/T-cell nasal-type lymphoma the treatment should
include L-asparaginase and local (nasopharyngeal)
radiotherapy.
Level of evidence: III
Grade of recommendation: B
3.4 Consensus statement
For patients with poor-risk TCL (IPI or PIT ≥2) with a
chemosensitive disease (in CR or PR) after induction
chemotherapy ASCT should be delivered.
Level of evidence: III
Grade of recommendation: B
3.4 Relapsed TCL treatment
Incidence: Around 70% of patients with TCL are refractory to
first-line therapy or relapse of their disease. Relapsing TCL can
have an aggressive course with the development of life
threatening complications. Hence diagnostic procedures,
staging and therapeutic decision might be done in emergency
and hectic situations. Histological verification should be
obtained in any situation, but it would be mandatory in
relapses of more than 12 months of the initial diagnosis.
Immunophenotype and level of expression of some markers
with therapeutic relevance should be investigated (CD30,
CD52, CD4, etc). Staging and risk assessment should be
carried out as per first diagnosis procedures.
The treatment choice differs depending on age and fitness.
Owing to the dismal prognosis of these malignancies in this
setting, an allogeneic transplant procedure is contemplated in
patients either with high-risk feature or in relapse after front-
line autologous SCT.
In the elderly and/or unfit patients, the treatment will be
palliative, although due to the favourable therapeutic index of
some new drugs used in monotherapy, these patients may be
enrolled in clinical trials with these agents.
Salvage therapy before ASCT
Conventional platinum-based regimens such as DHAP,
ESHAP, or ICE as used in DLBCL larger group may be offered
Table 6. List of markers applicable to formalin-fixed, paraffin-embedded
tissue sections for the diagnosis of peripheral NK-/TCLs
Mandatory diagnostic T-cell markers
CD2, CD3, CD4, CD5, CD7, CD8, (βF1), (TCRγ)
Optional markers for subtype distinction
Cytotoxic markers: TIA1, granzyme B, perforin
FTH markers: CD10, Bcl6, PD1, CXCL13, SAP, ICOS, CCR5
Treg markers: FoxP3
NK-cell markers: CD16, CD56, CD57
Activation markers: CD25, CD30
Others: CCR4, ALK, EMA, CD45
Proliferation: MIB1/Ki-67
B-cell markers: CD20, BSAP/PAX5
Follicular dendritic cells: CD21
Histiocytes and epithelioid elements: CD68/PG-M1
EBV: EBER ISH, LMP1, EBNA2
FTH, follicular helper T cell; ISH, in situ hybridization; TCR, T-cell
receptor.
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and are usually applied in such patients. The efficacy of these
regimens in TCL is not well known as no large published study
is available in these lymphomas. In general terms the response
rate might not exceed 50% with a small number of CRs with a
short duration of response.
The addition of gemcitabine in these combinations is based
on strong activity as a single agent in cutaneous TCL [143].
The GEM-P (gemcitabine, cis-platinum, and
methylprednisolone) offer a 69% ORR and a 19% CR rate in a
small series of relapsing patient [144]. The GIFOX
combination (gemcitabine, ifosfamide, and oxaliplatin)
recently tested in untreated TCL (ALCL excluded) with 86%
ORR and 67% CR could also be an alternative [145].
Alemtuzumab the anti-CD52-targeted monoclonal antibody
has been tested in monotherapy in relapsing TCL and in
combination with various chemotherapy (including DHAP)
[146, 147]. In the salvage setting, there is a 33%–61% response
rate including 33%–39% CRs, however with substantial
toxicity, a sizeable rate of fatal infections including EBV
reactivation. A close monitoring of patients treated with
alemtuzumab-containing regimens is warranted. ALCL whose
CD52 expression on tumour cells is uncommon are not
candidate for alemtuzumab treatment.
New agents used in monotherapy as pralatrexate,
romidepsin, and bendamustine can provide a 29%–47% ORR
with 11%–29% CR rate with acceptable toxicity [148–150].
Combinations of these agents with poly-chemotherapy have
not been reported yet in TCL. Such agents could still be used
in monotherapy, especially in the elderly patients. Brentuximab
vedotin has shown promising activity in pre-treated ALCL
ALK-negative patients, with >50% of the patients attaining
durable CR (see Section 3.5 “new drugs”). In any case, there is
no evidence that these new agents are superior to standard
salvage regimens widely used in the treatment of DLBCL.
In young and elderly fit patients, intensive salvage therapy
with cure intention should be undertaken. High-dose
chemotherapy with autologous SCT consolidation for
chemosensitive disease is the standard salvage therapy in
relapse/refractory aggressive lymphoma patients able to tolerate
this therapeutic modality. This strategy is implemented in TCL
on the assumption of a similar outcome as in DLBCL.
Consolidation with autologous SCT
Autologous SCT in relapsing TCL appears to provide a
40%–80% CR and a reported OS at 5 years of 40%–70% in
retrospective studies (see Table 7) [151, 152].
Most studies, especially those excluding ALK-positive TCL,
showed PFS curves with no plateau; a complete remission
status before auto-SCT is needed for a favourable outcome.
Also, high-risk patients, such as those with a high IPI score,
high β2-microglobulin, and chemorefractory disease have a
very poor prognosis.
No risk system has been specifically designed to select
patients that benefit from this therapeutic modality and
conversely that do not benefit and other alternative should be
undertaken. However, Rodriguez et al. proposed a risk system
based on two discrete variables aa-IPI and β2-microglobulin
able to segregate three groups of patients with distinct
prognosis with ASCT. In fact, patients with no presence of
aa-IPI >1 and normal level of β2-microglobulin benefit
substantially of these therapeutic procedures. In contrast, no
benefit is obtained in patients that present both variables at
relapse [153]. The quality of the response to the salvage
induction regimen before the transplant might also be
important as patients in CR pre-transplant according to most
series do better. However, with the current information, it is
not known whether patients in PR or CR differ in the outcome
with the transplant. A patients refractory to front-line therapy
and chemorefractory relapses have a dismal prognosis with an
autologous SCT, an allogeneic SCT is being studied in this
population.
Allogeneic transplantation
Based on preliminary results, allo-SCT can be considered as a
therapeutic option in the setting of relapsed T-cell lymphomas.
Moreover, ongoing clinical trials are testing the hypothesis of
allo-SCT as upfront strategy in patients affected by high-risk
disease. The advantage provided by an allo-SCT may reside on
two factors:
T cells can be a good target for donor-derived immune cells:
the so called ‘graft-versus-lymphoma’ effect; allogeneic grafts
are free from tumour cell contamination. Nevertheless,
whether or not the postulated graft-versus-lymphoma effect
may overcome the poor prognosis of patients with T-cell NHL
has not yet been established. In fact, the assessment of the role
of allo-SCT is limited by the following factors:
most of the studies are retrospective; the number of patients
is usually limited; different histologic subtypes are often
analysed together; many studies have included both refractory
and relapsed patients.
Survival after myeloablative allo-SCT has been influenced by
the high non-relapse mortality (NRM). Comparative trials of
auto- versus allo-SCT have some selection bias because usually
patients enrolled in the allograft cohort have more advanced
disease, more prior therapies and/or bone marrow
involvement. However, these studies demonstrated that
allografting induced a lower relapse risk when compared with
Table 7. Retrospective studies of auto-SCT in relapsed T-NHL
References N CR (%) OS
152 64 ND 70% (5 years)
169 29 79 39% (3 years)
170 40 80 58% (3 years)
171 36 42 48% (3 years)
172 78 68 56% (5 years)
173 28 50 69% (3 years)
174 37 76 54% (5 years)
175 24 63 33% (5 years)
176 40 60 Median 11.5 months
177 64 ND 49% (2 years)
178 123 73 45% (5 years)
153 25 ND 45% (2 years)
179 55 ND 45% (5 years)
CR, complete response; N, number of patients; ND, not done; OS, overall
survival.
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auto-SCT, but the high NRM offset any survival benefit
[154, 155].
Allo-SCT with RIC regimens is usually associated to a lower
NRM compared with myeloablative transplants; therefore, this
strategy can be offered to the elderly or heavily pre-treated
patients. In a pilot prospective study, we, first, reported the
outcome of 17 patients with relapsed TCL receiving a RIC
allo-SCT based on thiothepa—fludarabine—cyclophosphamide
[156].
In the recent literature on RIC-allotransplant in TCL, there
were some clinical results suggesting the existence of a graft-
versus-T lymphoma effect, because of achievement of durable
response with allografting in patients relapsed after an auto-
SCT and clinical responses to DLIs.
Recently, Dodero et al. have extended and corroborated their
previous observation that allografting may overcome the
unfavourable prognostic impact of T-cell phenotype reporting
the retrospective results of 52 patients [157]. The cumulative
incidence of NRM was 12% at 5 years. In multivariate analysis,
refractory disease and age >45 years were independent adverse
prognostic factors.
Other retrospective studies analysed the results of particular
subtypes of T-cell NHL. The British group published the data
about 45 patients affected by AITL underlying that more than
half of the patients may experience long-term survival after an
allo-SCT [158].
More limited experiences have been reported about acute
T-cell leukaemia/lymphoma and NK-lymphoma, providing the
evidence that allo-SCT is feasible and can produce responses
also in these patients [159–161].
3.5 Consensus statement
Second-line treatment of refractory/relapsed TCL should
contain one or more than one among the following drugs:
platinum, gemcitabine.
Level of evidence: IV
Grade of recommendation: B
3.6 Consensus statement
Auto-SCT should be considered for relapsed/refractory
TCL-NOS as well as ALK-negative ALCL and AITL.
Level of evidence: III
Grade of recommendation: B
3.7 Consensus statement
Allo-SCT in relapsed/refractory TCL (TCL-NOS, ALCL ALK−,
and AITL) proved to be the only curative treatment of this
patient subset (provided by retrospective studies).
Level of evidence: III
Grade of recommendation: A
3.5 New drugs
While current salvage regimens show some promise, what is
more exciting is the expanding number of new drugs being
studied specifically in TCL. In particular, available drugs such
as alemtuzumab and bortezomib are being included in
combination regimens for TCL [146, 147, 162]. Other agents
such as nelarabine, clofarabine, lenalidomide, and mTOR
inhibitors or new antibodies are either being studied or have
shown anedoctal activity in TCL [163–166]. While these new
uses of approved drugs are adding to an elongating list of
useful or promising therapies for TCL, there are currently only
two drugs specifically studied and FDA approved for the
treatment of relapsed/refractory TCL:
• Pralatrexate is a novel antifolate designed for higher affinity
for RFC-1 (reduced folate carrier) and increased poly-
glutamation, resulting in increased internalization and
retention of the drug in tumours. Promising results was seen
in a phase I–II trial. A multicentre registration phase II study
of pralatrexate in 111 relapsed or refractory TCL has
confirmed an ORR of 29% including 11% of CR [148].
• Romidepsin, a histone deacetylase inhibitor (HDACi),
followed a similar pattern to pralatrexate with early activity
seen in cutaneous TCL [167]. HDACi inhibit enzymes that
regulate acetylation of core nucleosomal histones as well as
other proteins. An international prospective multicentre
phase II of romidepsin in 130 relapsed/refractory TCL has
recently completed reporting an ORR of 30% and a CR rate
of 16% [149].
Monoclonal antibodies being studied for TCL include
especially anti-CD30 antibodies. CD30 is uniformly expressed
in ALCL and in ∼30% of cases of TCL—not otherwise
specified. SGN-35, an antibody-drug conjugate brentuximab
vedotin (SGN-35) delivers the highly potent anti-microtubule
agent monomethyl auristatin E (MMAE) to CD30-positive
malignant cells by binding specifically to CD30 on the cell
surface and releasing MMAE inside the cell via lysosomal
degradation. In particular, a phase II international multicentre
study in 58 relapsed or refractory ALCL patients showed an
ORR of 87% with a CR rate of 57% [168].
3.8 Consensus statement
Refractory relapsed TCL should be enrolled, whenever possible,
in phase I or II prospective clinical trials aimed at exploring
the efficacy of new drugs that have shown activity in
pre-clinical studies.
Level of evidence: IV
Grade of recommendation: B
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